Literature DB >> 8224269

Expression of major histocompatibility complex class II antigen in endometriotic tissue in patients with endometriosis and adenomyosis.

H Ota1, S Igarashi.   

Abstract

OBJECTIVE: To evaluate the expression of major histocompatibility complex class II antigen (human leukocyte antigen, HLA-DR) in glandular cells in eutopic and ectopic endometria in patients with endometriosis and adenomyosis. PATIENTS: Subjects consisted of 50 patients with adenomyosis and 18 patients with endometriosis. Controls consisted of 17 patients with adenomyoma and 42 infertile women without habitual abortion and autoimmune diseases.
DESIGN: Glandular cells in eutopic and ectopic endometria were analyzed immunohistochemically to localize the expression of HLA-DR antigen. The sections were scored from 0 to 5 according to the evaluation nomogram.
RESULTS: Immunohistochemical analysis revealed significantly increased expression of HLA-DR antigen in the glandular cells in eutopic and ectopic endometria, compared with materials from patients with adenomyoma and infertile patients.
CONCLUSIONS: It is likely that aberrant expression of HLA-DR antigen in glandular cells of eutopic and ectopic endometria in endometriosis and adenomyosis is deeply involved in various immunological abnormalities.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8224269     DOI: 10.1016/s0015-0282(16)56284-0

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  10 in total

1.  Association of pelvic endometriosis with alopecia universalis, autoimmune thyroiditis and multiple sclerosis.

Authors:  C Alviggi; P B Carrieri; R Pivonello; V Scarano; M Pezzella; G De Placido; A Colao; G Matarese
Journal:  J Endocrinol Invest       Date:  2006-02       Impact factor: 4.256

2.  Adenomyosis: Mechanisms and Pathogenesis.

Authors:  Junyu Zhai; Silvia Vannuccini; Felice Petraglia; Linda C Giudice
Journal:  Semin Reprod Med       Date:  2020-10-08       Impact factor: 1.303

3.  Immune interactions in endometriosis.

Authors:  Jennifer L Herington; Kaylon L Bruner-Tran; John A Lucas; Kevin G Osteen
Journal:  Expert Rev Clin Immunol       Date:  2011-09       Impact factor: 4.473

Review 4.  Medical management of endometriosis: emerging evidence linking inflammation to disease pathophysiology.

Authors:  K L Bruner-Tran; J L Herington; A J Duleba; H S Taylor; K G Osteen
Journal:  Minerva Ginecol       Date:  2013-04

5.  Role of reactive oxygen species in gynecologic diseases.

Authors:  Rakesh K Sharma; Ashok Agarwal
Journal:  Reprod Med Biol       Date:  2004-12-03

6.  Immunohistochemical study of HLA-DR antigen in endometrial tissue of patients with endometriosis.

Authors:  Yi Liu; Lilan Luo; Haibo Zhao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2002

7.  The possible anti-inflammatory role of circulating human leukocyte antigen levels in women with endometriosis after treatment with danazol and leuprorelin acetate depot.

Authors:  I M Matalliotakis; I Athanassakis; A G Goumenou; M A Neonaki; E E Koumantakis; S Vassiliadis; E E Koumantakis
Journal:  Mediators Inflamm       Date:  2001-04       Impact factor: 4.711

Review 8.  Molecular aspects of development and regulation of endometriosis.

Authors:  Yana B Aznaurova; Marat B Zhumataev; Tiffany K Roberts; Alexander M Aliper; Alex A Zhavoronkov
Journal:  Reprod Biol Endocrinol       Date:  2014-06-13       Impact factor: 5.211

9.  The Effects of Dienogest on Macrophage and Natural Killer Cells in Adenomyosis: A Randomized Controlled Study.

Authors:  Saowapak Prathoomthong; Yada Tingthanatikul; Srithean Lertvikool; Nittaya Rodratn; Wanwisa Waiyaput; Kanthanadon Dittharot; Morakot Sroyraya; Areepan Sophonsritsuk
Journal:  Int J Fertil Steril       Date:  2017-10-12

Review 10.  The Pathogenesis of Endometriosis: Molecular and Cell Biology Insights.

Authors:  Antonio Simone Laganà; Simone Garzon; Martin Götte; Paola Viganò; Massimo Franchi; Fabio Ghezzi; Dan C Martin
Journal:  Int J Mol Sci       Date:  2019-11-10       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.